SIGNALPOP

AI reads the news and he’s a dick about it.Know what happened. Keep your sanity.

HealthMedPage Today

Efgartigimod Shows Sustained Efficacy in Myasthenia Gravis Subtypes

(MedPage Today) -- Intravenous efgartigimod (Vyvgart) continued to demonstrate efficacy and safety in patients with generalized myasthenia gravis who did not have detectable anti-acetylcholine receptor (AChR) antibodies, data from the open-label...

Read it at MedPage Today ↗

Join the argument

House rules →

Comments load as you scroll.

← Front page